Back Hepatitis C

Hepatitis C

Telaprevir Label Gets Black Box Warning about Serious Skin Rash

The U.S. Food and Drug Administration (FDA) announced this week that the hepatitis C protease inhibitor telaprevir (Incivek) label will be updated to include a "Black Box" safety warning after the agency received reports of serious and potentially fatal skin reactions.


Hepatitis C Sexual Transmission Is Rare among Monogamous Heterosexual Couples

Transmission of hepatitis C virus (HCV) between long-term, monogamous, heterosexual partners can potentially occur, but appears to be very uncommon, according to a study of 500 couples described in the November 23, 2012, advance online edition of Hepatology. Furthermore, the analysis failed to find a link between HCV transmission and any specific sexual activities.


AASLD 2012: Telaprevir and VX-222 Pair Well in Interferon-free Regimens, VX-135 on the Horizon

An all-oral regimen of telaprevir, VX-222, and ribavirin for 12 weeks was generally well-tolerated and produced sustained response in approximately 70% of previously untreated chronic hepatitis C patients, including those with hard-to-treat HCV subtype 1a, according to study findings presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston.alt

HIV11: Sexually Transmitted HCV Rising among HIV+ Gay Men in Europe, but More Are Getting Treated

Hepatitis C virus (HCV) infection rates continue to rise among HIV positive people in Europe, with the highest incidence among injection drug users and men who have sex with men, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection last month in Glasgow. Another study, however, found that HIV/HCV coinfected people are now more likely to receive hepatitis C treatment.


Eltrombopag Approved for Managing Low Platelets to Enable Hepatitis C Patients to Use Interferon

The U.S. Food and Drug Administration has approved a new indication for eltrombopag (Promacta or Revolade), supporting its use for management of thrombocytopenia, or low platelet count, in people with chronic hepatitis C, GlaxoSmithKline announced last week. alt

AASLD 2012: Is a Simple Sofosbuvir + Ribavirin Regimen Suitable for Hard-to-treat HCV Patients?

An all-oral dual regimen of sofosbuvir plus full-dose ribavirin was well-tolerated and produced 4-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot study, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. Reducing the ribavirin dose, however, lowered response rates.alt

AASLD 2012: Avatrombopag Reduces Bleeding Risk for Liver Disease Patients Undergoing Surgery

The experimental thrombopoietin receptor agonist avatrombopag (E5501) effectively increased platelet counts in patients with chronic liver disease enough to enable them to safely undergo scheduled surgeries, according to data presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston. alt

Task Force Recommends Hepatitis C Screening for Baby Boomers, but Data Inconclusive

Adults born between 1945 and 1965 should consider screening for hepatitis C, with a stronger recommendation for people with risk factors such as a history of injection drug use or blood transfusions before 1992, according to draft recommendations from the U.S. Preventive Services Task Force (USPSTF). A set of literature reviews, however, found that data on the benefits of testing are lacking.alt

AASLD 2012: Telaprevir Twice-daily Works as Well as Every 8 Hours, Safe for Hep C Patients with Cirrhosis

The HCV protease inhibitor telaprevir (Incivek) taken twice-daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved 3-times-daily schedule, with similar safety and tolerability even for people with advanced liver fibrosis, according to study findings presented last week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston. alt